News

Filter

Current filters:

DepomedSerada

Depomed shares plummet as Ph III Serada trial fails one endpoint

17-10-2011

Shares of US specialty drugmaker Depomed (Nasdaq: DEPO) fell 28.2% to $4.52 last Friday, after the company…

DepomedgabapentinNeurologicalPharmaceuticalResearchSerada

COMPANY SPOTLIGHT

Menarini

Back to top